Biotech is a strange world, one where investors often seem to prefer
stories that are relatively weak on sales, earnings, and actual data.
Maybe that makes a certain amount of sense - in the absence of data,
investors are free to dream about blockbuster drugs and multi-baggers.
In the case of Alkermes (ALKS),
it would seem that having an actual cash flow-generating business is
almost a detriment to the stock. Given that I believe Alkermes combines a
strong (and fairly stable) royalty-generating business with a
high-risk/high-reward, but undervalued, pipeline, I believe this is a
stock worth considering even at these relatively elevated prices for
biotech stocks.
Please continue here:
Alkermes Still Not Getting Full Credit For Its Pipeline
No comments:
Post a Comment